ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: SA-PO803

The Value of Advanced Cardiac Magnetic Resonance Imaging Technologies in Detecting the Characteristics of Cardiac Involvement in Anderson-Fabry Disease

Session Information

Category: Genetic Diseases of the Kidneys

  • 1202 Genetic Diseases of the Kidneys: Non-Cystic

Authors

  • Yang, Junlan, Southeast University, Nanjing, Jiangsu, China
  • Wang, Bin, Southeast University, Nanjing, Jiangsu, China
Background

Anderson-Fabry disease (AFD) is a genetic disorder associated with cardiac involvement. Advanced cardiac magnetic resonance (CMR) technologies, including T1 mapping and gadolinium-enhanced CMR, have been used to detect and evaluate cardiac involvement in AFD patients. However, there is limited information on the characteristic CMR manifestations in Chinese AFD patients.

Methods

In this cross-sectional study, data were collected from patients with AFD diagnosed at this center from January 2022 to March 2023. Compared with echocardiography, CMR was used to evaluate cardiac function, the degree of cardiac structural lesions, and to analyze characteristic CMR findings in AFD.

Results

20 patients with AFD from nine families were included. This study showed that left ventricular hypertrophy (LVH) was detected in 85% of patients (18.41 ± 4.56 mm) by CMR, whereas echocardiography identified LVH in only 65% of patients (16.86 ± 2.74 mm), suggesting that echocardiography may underestimate the severity of LVH in AFD patients (P=0.001). Moreover, all patients exhibited characteristic CMR findings of cardiac involvement in AFD (Fig.1, Fig.2), including decreased T1 values (95% of patients) and late gadolinium enhancement (LGE) associated with myocardial fibrosis (55% of patients).

Conclusion

This study demonstrated that CMR is a valuable tool for detecting and assessing cardiac involvement in AFD patients, providing characteristic CMR findings, including LVH, decreased T1 values, and LGE associated with myocardial fibrosis. Moreover, this study highlighted the diagnostic superiority of CMR over echocardiography in assessing LVH in AFD patients.